focus -WSS

focus

author：hotspot 2025-09-30 01:12:27 - browse：1

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： It's been 20 years since Dolly the sheep. Where's my clone?

hotspot

leisure time

WSS

Senators: Long

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

CommonSpirit Health keeps growing, even as it loses money

Changes to biosimilar regulatory framework must prioritize patients

Addiction experts warn against a second 'war on drugs'

Intarcia’s device

focus

focus

Wikipedia

Anesthesiologist group: stop taking Ozempic before surgery

Case highlights the risks of experimental stem cell therapy

Anesthesiologist group: stop taking Ozempic before surgery

Readout LOUD podcast: possible new ALS drug, artificial wombs

Novavax promises a turnaround & Lilly roils the obesity market

FDA panel to weigh approval of NurOwn, controversial ALS drug

How one medical school became remarkably diverse

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout LOUD podcast: possible new ALS drug, artificial wombs

leisure time

CommonSpirit Health keeps growing, even as it loses money

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Readers respond to H5N1 and livestock movements, and more

NVIDIA and Google execs on the future of AI and drug discovery

Thermo Fisher plant for manufacturing gene therapies to expand

Emergency workers more likely to restrain Black patients: study

focus

hotspot

leisure time

explore